ReviewApplied biochemistry and biotechnology2026
Comprehensive Research Progress on Glucosamine: A Review.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Valorization Potential of Freshwater Fish, Including Common Carp (Foods (Basel, Switzerland) · 2026Review
- Glucosamine Yield Improvement in EngineeredFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
As one of the important derivatives of D-glucose, Glucosamine (GlcN) is an amino monosaccharide with various biological activities. GlcN has functions such as enhancing immunity, antioxidation, and antibacterial effects, and it is particularly well known for its role in the treatment of osteoarthritis. This also gives GlcN broad application prospects in the fields of healthcare, food production, and cosmetics, with its global market size projected to exceed 10 billion USD by 2028. As demand grows, its efficient industrial production has been attracting increasing attention. Here, we systematically introduce the functions, raw material sources, metabolic pathways, detection methods, and applications of GlcN in various countries. Particularly, we delve into the strategies for high-yield biosynthesis of GlcN/GlcNAc using metabolically engineered microorganisms, with the highest reported titer reaching 179.7 g/L. This comprehensive overview aims to help readers gain a better understanding of GlcN and explore its potential commercial value and product applications.
Indexed as
Identifiers
41528379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.